Comparison of Use of Intralesional Artemether with Intralesional Meglumine Antimoniate in Cutaneous Leishmaniasis
Objective: The objective of this study is to compare the efficacy and safety of Intralesional Meglumine Antimoniate and Intralesional Artemether in the Treatment of Cutaneous Leishmaniasis.
Patients and Methods: Total 168 patients of cutaneous leishmaniasis were assigned randomly and equally to intralesional meglumine antimoniate (group A) and intralesional artemether (group B). The study outcome was measured after 6 weeks of therapy and treatment was considered efficacious if the lesion reduced more than 75% from its baseline size. The side effects in terms of pain, redness and swelling at the site of injection, fever, hepatitis and renal impairment were also noted.
Results: Intralesional meglumine antimoniate achieved complete healing in 75 (89.3%) cases compared to 62 (73.8%) cases in intralesional artemether (p= 0.01).
Conclusion: Intralesional meglumine antimoniate is better than intralesional artemether in the treatment of cutaneous leishmaniasis. Both drugs were found safe and no significant side effects were noted.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.